Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 111 | 2024 | 17354 | 6.570 |
Why?
|
South Africa | 62 | 2024 | 1843 | 4.510 |
Why?
|
Refugees | 10 | 2022 | 596 | 2.480 |
Why?
|
CD4 Lymphocyte Count | 27 | 2024 | 2571 | 2.350 |
Why?
|
Anti-HIV Agents | 23 | 2024 | 4527 | 1.900 |
Why?
|
Mobile Health Units | 4 | 2019 | 92 | 1.900 |
Why?
|
Mass Screening | 20 | 2019 | 5429 | 1.730 |
Why?
|
Contraception | 3 | 2021 | 349 | 1.610 |
Why?
|
Continuity of Patient Care | 8 | 2021 | 1069 | 1.560 |
Why?
|
Ambulatory Care Facilities | 10 | 2024 | 935 | 1.480 |
Why?
|
Tuberculosis, Pulmonary | 7 | 2024 | 832 | 1.440 |
Why?
|
Cryptococcus | 3 | 2021 | 28 | 1.430 |
Why?
|
Antigens, Fungal | 3 | 2021 | 69 | 1.410 |
Why?
|
Beauty Culture | 2 | 2019 | 41 | 1.290 |
Why?
|
Tuberculosis | 9 | 2024 | 2017 | 1.230 |
Why?
|
AIDS Serodiagnosis | 4 | 2014 | 220 | 1.190 |
Why?
|
Uganda | 19 | 2024 | 1332 | 1.140 |
Why?
|
Point-of-Care Systems | 6 | 2021 | 1213 | 1.110 |
Why?
|
Sarcoma, Kaposi | 7 | 2024 | 374 | 1.100 |
Why?
|
Mycobacterium tuberculosis | 7 | 2019 | 1914 | 1.070 |
Why?
|
Lipopolysaccharides | 5 | 2018 | 2206 | 1.030 |
Why?
|
Chlamydia Infections | 3 | 2024 | 365 | 1.000 |
Why?
|
AIDS-Related Opportunistic Infections | 4 | 2020 | 662 | 0.980 |
Why?
|
Gonorrhea | 3 | 2024 | 346 | 0.980 |
Why?
|
Anti-Retroviral Agents | 12 | 2022 | 1784 | 0.960 |
Why?
|
Antiretroviral Therapy, Highly Active | 9 | 2024 | 1897 | 0.960 |
Why?
|
Diagnostic Tests, Routine | 4 | 2015 | 787 | 0.910 |
Why?
|
Sexually Transmitted Diseases | 3 | 2024 | 662 | 0.870 |
Why?
|
Patient Acceptance of Health Care | 9 | 2023 | 3206 | 0.780 |
Why?
|
Meningitis, Cryptococcal | 2 | 2021 | 67 | 0.780 |
Why?
|
Health Knowledge, Attitudes, Practice | 5 | 2022 | 4016 | 0.740 |
Why?
|
Adult | 87 | 2024 | 221210 | 0.730 |
Why?
|
Reagent Kits, Diagnostic | 3 | 2018 | 239 | 0.720 |
Why?
|
Internationality | 2 | 2018 | 1001 | 0.710 |
Why?
|
Contraceptive Agents | 1 | 2021 | 144 | 0.690 |
Why?
|
Social Support | 5 | 2022 | 2172 | 0.680 |
Why?
|
Qualitative Research | 11 | 2024 | 3025 | 0.670 |
Why?
|
Community Health Services | 4 | 2021 | 656 | 0.660 |
Why?
|
Focus Groups | 5 | 2024 | 1415 | 0.620 |
Why?
|
HIV Seropositivity | 4 | 2013 | 960 | 0.600 |
Why?
|
Viral Load | 7 | 2024 | 3332 | 0.590 |
Why?
|
Female | 93 | 2024 | 392705 | 0.580 |
Why?
|
Acquired Immunodeficiency Syndrome | 4 | 2022 | 2199 | 0.580 |
Why?
|
Male | 86 | 2024 | 360846 | 0.580 |
Why?
|
Humans | 141 | 2024 | 761596 | 0.580 |
Why?
|
Prevalence | 19 | 2024 | 15733 | 0.570 |
Why?
|
Comprehensive Health Care | 1 | 2016 | 123 | 0.510 |
Why?
|
Lost to Follow-Up | 2 | 2017 | 123 | 0.510 |
Why?
|
Health Resources | 5 | 2014 | 935 | 0.500 |
Why?
|
Public Sector | 1 | 2017 | 267 | 0.490 |
Why?
|
Social Stigma | 7 | 2024 | 769 | 0.490 |
Why?
|
Maternal Mortality | 1 | 2018 | 302 | 0.490 |
Why?
|
Prospective Studies | 30 | 2023 | 54423 | 0.480 |
Why?
|
Hair | 1 | 2018 | 498 | 0.480 |
Why?
|
Influenza Vaccines | 1 | 2022 | 768 | 0.480 |
Why?
|
HIV-1 | 8 | 2020 | 6863 | 0.480 |
Why?
|
Patient Transfer | 2 | 2019 | 794 | 0.470 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2020 | 4369 | 0.470 |
Why?
|
Rural Population | 4 | 2024 | 2287 | 0.470 |
Why?
|
Cryptococcosis | 1 | 2015 | 104 | 0.470 |
Why?
|
Postpartum Period | 2 | 2018 | 1175 | 0.450 |
Why?
|
Case Management | 2 | 2021 | 272 | 0.440 |
Why?
|
Voluntary Programs | 3 | 2014 | 48 | 0.440 |
Why?
|
Medically Underserved Area | 1 | 2015 | 254 | 0.430 |
Why?
|
Geographic Information Systems | 1 | 2015 | 281 | 0.430 |
Why?
|
Sputum | 6 | 2018 | 506 | 0.430 |
Why?
|
Young Adult | 34 | 2024 | 59260 | 0.420 |
Why?
|
Pregnancy Complications, Infectious | 3 | 2024 | 2151 | 0.420 |
Why?
|
Trichomonas Infections | 2 | 2023 | 41 | 0.420 |
Why?
|
HIV | 6 | 2022 | 1582 | 0.410 |
Why?
|
Health Services Research | 2 | 2017 | 1812 | 0.400 |
Why?
|
Nucleic Acid Amplification Techniques | 1 | 2014 | 330 | 0.400 |
Why?
|
Delayed Diagnosis | 2 | 2022 | 463 | 0.390 |
Why?
|
Sexual Partners | 4 | 2024 | 796 | 0.390 |
Why?
|
Homosexuality, Male | 4 | 2024 | 1334 | 0.390 |
Why?
|
Forecasting | 1 | 2020 | 2928 | 0.380 |
Why?
|
Influenza, Human | 1 | 2022 | 1521 | 0.370 |
Why?
|
HIV Seroprevalence | 1 | 2011 | 89 | 0.360 |
Why?
|
Counseling | 4 | 2023 | 1547 | 0.360 |
Why?
|
Outpatients | 4 | 2021 | 1597 | 0.360 |
Why?
|
Delivery of Health Care | 7 | 2023 | 5337 | 0.340 |
Why?
|
Clinical Trials as Topic | 2 | 2018 | 8002 | 0.340 |
Why?
|
Behavior Therapy | 1 | 2015 | 879 | 0.340 |
Why?
|
Bacteriological Techniques | 1 | 2010 | 275 | 0.330 |
Why?
|
Placenta Diseases | 2 | 2021 | 199 | 0.320 |
Why?
|
Health Services Accessibility | 4 | 2017 | 5440 | 0.320 |
Why?
|
Middle Aged | 37 | 2024 | 220921 | 0.310 |
Why?
|
Medical Assistance | 1 | 2008 | 108 | 0.300 |
Why?
|
Sensitivity and Specificity | 9 | 2021 | 14665 | 0.300 |
Why?
|
Adolescent | 28 | 2024 | 88326 | 0.290 |
Why?
|
Cohort Studies | 17 | 2024 | 41495 | 0.290 |
Why?
|
Medication Adherence | 4 | 2024 | 2176 | 0.290 |
Why?
|
Attitude of Health Personnel | 1 | 2021 | 3889 | 0.290 |
Why?
|
RNA, Viral | 4 | 2015 | 2846 | 0.280 |
Why?
|
Kenya | 7 | 2024 | 758 | 0.280 |
Why?
|
Motivation | 2 | 2023 | 2006 | 0.280 |
Why?
|
Trust | 2 | 2022 | 530 | 0.270 |
Why?
|
Contact Tracing | 3 | 2024 | 271 | 0.270 |
Why?
|
Cross-Sectional Studies | 11 | 2024 | 26129 | 0.270 |
Why?
|
Patient Satisfaction | 3 | 2015 | 3462 | 0.260 |
Why?
|
Serologic Tests | 2 | 2019 | 381 | 0.260 |
Why?
|
Government Programs | 1 | 2007 | 279 | 0.250 |
Why?
|
Family Characteristics | 2 | 2023 | 1004 | 0.240 |
Why?
|
Needlestick Injuries | 1 | 2004 | 71 | 0.230 |
Why?
|
Tuberculosis, Multidrug-Resistant | 1 | 2012 | 934 | 0.230 |
Why?
|
Hypothermia | 2 | 2022 | 188 | 0.220 |
Why?
|
Blood Sedimentation | 2 | 2022 | 235 | 0.220 |
Why?
|
Subacute Care | 2 | 2023 | 179 | 0.200 |
Why?
|
Fibrin Fibrinogen Degradation Products | 2 | 2022 | 422 | 0.200 |
Why?
|
Feasibility Studies | 3 | 2018 | 5247 | 0.200 |
Why?
|
Pandemics | 6 | 2023 | 8656 | 0.190 |
Why?
|
Syphilis | 1 | 2024 | 243 | 0.180 |
Why?
|
Health Behavior | 1 | 2012 | 2644 | 0.180 |
Why?
|
Drug Users | 1 | 2022 | 134 | 0.180 |
Why?
|
Fluconazole | 1 | 2021 | 157 | 0.180 |
Why?
|
Placenta | 4 | 2023 | 1709 | 0.180 |
Why?
|
Pregnancy | 12 | 2024 | 29890 | 0.180 |
Why?
|
Directly Observed Therapy | 1 | 2021 | 139 | 0.180 |
Why?
|
Drug Resistance, Multiple, Bacterial | 2 | 2017 | 587 | 0.180 |
Why?
|
Systemic Inflammatory Response Syndrome | 2 | 2022 | 621 | 0.170 |
Why?
|
Africa South of the Sahara | 5 | 2024 | 744 | 0.170 |
Why?
|
Massachusetts | 5 | 2024 | 8833 | 0.170 |
Why?
|
Interviews as Topic | 3 | 2024 | 2696 | 0.170 |
Why?
|
Severity of Illness Index | 7 | 2021 | 15843 | 0.170 |
Why?
|
Biomarkers, Pharmacological | 1 | 2020 | 161 | 0.170 |
Why?
|
Thoracostomy | 1 | 2019 | 74 | 0.160 |
Why?
|
Pregnancy, Unwanted | 1 | 2018 | 24 | 0.160 |
Why?
|
Pharmacies | 1 | 2021 | 169 | 0.160 |
Why?
|
Puerperal Infection | 1 | 2018 | 44 | 0.150 |
Why?
|
Immunologic Tests | 1 | 2019 | 104 | 0.150 |
Why?
|
Socioeconomic Factors | 4 | 2019 | 7828 | 0.150 |
Why?
|
Asymptomatic Infections | 1 | 2019 | 131 | 0.150 |
Why?
|
Retrospective Studies | 15 | 2023 | 80647 | 0.150 |
Why?
|
Substance Abuse, Intravenous | 1 | 2022 | 529 | 0.150 |
Why?
|
Viremia | 2 | 2022 | 707 | 0.150 |
Why?
|
DNA, Bacterial | 2 | 2014 | 1479 | 0.150 |
Why?
|
Nigeria | 5 | 2020 | 770 | 0.150 |
Why?
|
Acinetobacter | 1 | 2017 | 39 | 0.140 |
Why?
|
Cost-Benefit Analysis | 5 | 2022 | 5493 | 0.140 |
Why?
|
Radiography, Thoracic | 2 | 2024 | 1302 | 0.140 |
Why?
|
Regression Analysis | 3 | 2016 | 6345 | 0.140 |
Why?
|
Risk Factors | 14 | 2023 | 74213 | 0.140 |
Why?
|
Acinetobacter Infections | 1 | 2017 | 73 | 0.140 |
Why?
|
Safety | 1 | 2021 | 1149 | 0.140 |
Why?
|
Hospitals, General | 1 | 2020 | 798 | 0.130 |
Why?
|
Antifungal Agents | 1 | 2021 | 753 | 0.130 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2022 | 612 | 0.130 |
Why?
|
Cephalosporins | 1 | 2017 | 198 | 0.130 |
Why?
|
Diabetes Mellitus | 3 | 2024 | 5841 | 0.130 |
Why?
|
Occupational Diseases | 1 | 2004 | 1490 | 0.130 |
Why?
|
Pneumothorax | 1 | 2019 | 386 | 0.130 |
Why?
|
Obesity | 4 | 2022 | 12947 | 0.130 |
Why?
|
Social Environment | 1 | 2020 | 1020 | 0.130 |
Why?
|
Patient Compliance | 3 | 2017 | 2690 | 0.130 |
Why?
|
Logistic Models | 4 | 2020 | 13255 | 0.120 |
Why?
|
Proportional Hazards Models | 2 | 2020 | 12463 | 0.120 |
Why?
|
Mental Disorders | 1 | 2015 | 6845 | 0.120 |
Why?
|
Educational Status | 1 | 2023 | 2522 | 0.120 |
Why?
|
Pilot Projects | 2 | 2019 | 8633 | 0.120 |
Why?
|
Prenatal Care | 1 | 2022 | 1141 | 0.120 |
Why?
|
Random Allocation | 1 | 2019 | 2395 | 0.120 |
Why?
|
Disclosure | 1 | 2020 | 748 | 0.120 |
Why?
|
Aged | 15 | 2024 | 169310 | 0.120 |
Why?
|
Public-Private Sector Partnerships | 1 | 2015 | 122 | 0.120 |
Why?
|
Odds Ratio | 4 | 2020 | 9647 | 0.120 |
Why?
|
Violence | 1 | 2020 | 937 | 0.120 |
Why?
|
Income | 1 | 2023 | 1877 | 0.110 |
Why?
|
Primary Health Care | 2 | 2021 | 4687 | 0.110 |
Why?
|
Interpersonal Relations | 1 | 2021 | 1436 | 0.110 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2019 | 610 | 0.110 |
Why?
|
Geography | 2 | 2013 | 656 | 0.110 |
Why?
|
Vascular Diseases | 1 | 2021 | 1161 | 0.110 |
Why?
|
Caregivers | 2 | 2017 | 2238 | 0.110 |
Why?
|
Immunoenzyme Techniques | 2 | 2019 | 1704 | 0.110 |
Why?
|
Streptomycin | 1 | 2012 | 69 | 0.100 |
Why?
|
Guidelines as Topic | 2 | 2010 | 1386 | 0.100 |
Why?
|
Patient Discharge | 2 | 2023 | 3443 | 0.100 |
Why?
|
Kanamycin | 1 | 2012 | 63 | 0.100 |
Why?
|
Depression | 1 | 2012 | 8126 | 0.100 |
Why?
|
Ethambutol | 1 | 2012 | 59 | 0.100 |
Why?
|
Bayes Theorem | 1 | 2020 | 2330 | 0.100 |
Why?
|
C-Reactive Protein | 2 | 2022 | 3826 | 0.100 |
Why?
|
Hepatitis C | 1 | 2022 | 1584 | 0.100 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2020 | 942 | 0.100 |
Why?
|
Drug Monitoring | 1 | 2018 | 962 | 0.100 |
Why?
|
Chi-Square Distribution | 1 | 2018 | 3415 | 0.100 |
Why?
|
United States | 8 | 2022 | 72340 | 0.100 |
Why?
|
Reproducibility of Results | 3 | 2021 | 20100 | 0.100 |
Why?
|
Urinalysis | 1 | 2014 | 368 | 0.100 |
Why?
|
Public Health Administration | 1 | 2013 | 242 | 0.090 |
Why?
|
Inflammation | 2 | 2021 | 10774 | 0.090 |
Why?
|
Hospitals, Rural | 1 | 2012 | 176 | 0.090 |
Why?
|
Gene Products, gag | 1 | 2011 | 312 | 0.090 |
Why?
|
Algorithms | 3 | 2018 | 14033 | 0.090 |
Why?
|
Isoniazid | 1 | 2012 | 283 | 0.090 |
Why?
|
Stereotyping | 1 | 2012 | 239 | 0.090 |
Why?
|
Antitubercular Agents | 2 | 2019 | 1375 | 0.090 |
Why?
|
Hospitals, Urban | 1 | 2012 | 500 | 0.090 |
Why?
|
Rifampin | 1 | 2012 | 339 | 0.090 |
Why?
|
Intensive Care Units | 2 | 2021 | 3744 | 0.090 |
Why?
|
Disease Transmission, Infectious | 1 | 2015 | 560 | 0.090 |
Why?
|
Vulnerable Populations | 1 | 2015 | 703 | 0.090 |
Why?
|
Hospital Mortality | 2 | 2020 | 5293 | 0.090 |
Why?
|
Vaccination | 1 | 2022 | 3384 | 0.090 |
Why?
|
Drug Administration Routes | 1 | 2010 | 150 | 0.080 |
Why?
|
False Negative Reactions | 1 | 2011 | 573 | 0.080 |
Why?
|
Health Care Surveys | 1 | 2017 | 2426 | 0.080 |
Why?
|
Program Evaluation | 2 | 2015 | 2495 | 0.080 |
Why?
|
Hospitalization | 5 | 2021 | 10721 | 0.080 |
Why?
|
Cytokines | 1 | 2024 | 7396 | 0.080 |
Why?
|
Multivariate Analysis | 4 | 2018 | 12059 | 0.080 |
Why?
|
Inpatients | 1 | 2020 | 2548 | 0.080 |
Why?
|
Developing Countries | 2 | 2012 | 2885 | 0.080 |
Why?
|
Incidence | 4 | 2023 | 21355 | 0.080 |
Why?
|
Cell Count | 1 | 2013 | 1835 | 0.080 |
Why?
|
Child | 8 | 2022 | 80158 | 0.080 |
Why?
|
Sex Factors | 2 | 2021 | 10554 | 0.080 |
Why?
|
Ambulatory Care | 2 | 2011 | 2775 | 0.080 |
Why?
|
Prejudice | 1 | 2012 | 570 | 0.080 |
Why?
|
Medical Record Linkage | 1 | 2010 | 285 | 0.080 |
Why?
|
Mortality | 1 | 2019 | 2902 | 0.070 |
Why?
|
Referral and Consultation | 3 | 2020 | 3600 | 0.070 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2011 | 828 | 0.070 |
Why?
|
Monitoring, Physiologic | 1 | 2015 | 1779 | 0.070 |
Why?
|
International Cooperation | 1 | 2013 | 1422 | 0.070 |
Why?
|
Follow-Up Studies | 4 | 2019 | 39106 | 0.070 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 3204 | 0.070 |
Why?
|
Peer Group | 2 | 2023 | 692 | 0.070 |
Why?
|
Infant, Newborn | 6 | 2023 | 26202 | 0.070 |
Why?
|
Communication | 1 | 2020 | 3875 | 0.070 |
Why?
|
Staining and Labeling | 1 | 2010 | 1085 | 0.070 |
Why?
|
Ultrasonography | 1 | 2019 | 5971 | 0.070 |
Why?
|
Urban Health | 1 | 2008 | 532 | 0.060 |
Why?
|
Substance-Related Disorders | 1 | 2022 | 4420 | 0.060 |
Why?
|
Infant | 4 | 2022 | 36193 | 0.060 |
Why?
|
Survival Analysis | 2 | 2019 | 10090 | 0.060 |
Why?
|
Outpatient Clinics, Hospital | 1 | 2007 | 395 | 0.060 |
Why?
|
Microscopy | 1 | 2010 | 903 | 0.060 |
Why?
|
Health Personnel | 2 | 2012 | 3335 | 0.060 |
Why?
|
Urban Population | 1 | 2012 | 2036 | 0.060 |
Why?
|
Self Care | 1 | 2009 | 796 | 0.060 |
Why?
|
Confidence Intervals | 1 | 2010 | 2927 | 0.060 |
Why?
|
World Health Organization | 1 | 2010 | 1322 | 0.060 |
Why?
|
Health Care Costs | 2 | 2014 | 3242 | 0.060 |
Why?
|
Age Factors | 3 | 2020 | 18399 | 0.060 |
Why?
|
Clinical Competence | 1 | 2019 | 4793 | 0.060 |
Why?
|
Patient Education as Topic | 1 | 2013 | 2319 | 0.050 |
Why?
|
Europe | 1 | 2010 | 3420 | 0.050 |
Why?
|
Hospitals | 1 | 2017 | 3883 | 0.050 |
Why?
|
Acute Disease | 2 | 2011 | 7237 | 0.050 |
Why?
|
Electronic Health Records | 1 | 2020 | 4811 | 0.050 |
Why?
|
Blotting, Western | 1 | 2011 | 5035 | 0.050 |
Why?
|
Blood Pressure | 1 | 2019 | 8481 | 0.050 |
Why?
|
Fever | 2 | 2022 | 1618 | 0.050 |
Why?
|
New Mexico | 1 | 2022 | 83 | 0.050 |
Why?
|
RNA | 2 | 2023 | 2725 | 0.050 |
Why?
|
Treatment Outcome | 4 | 2024 | 64685 | 0.050 |
Why?
|
Quality Indicators, Health Care | 1 | 2012 | 1792 | 0.050 |
Why?
|
Decision Trees | 1 | 2004 | 504 | 0.050 |
Why?
|
Tetanus Toxoid | 1 | 2022 | 189 | 0.050 |
Why?
|
Disease Progression | 2 | 2023 | 13510 | 0.050 |
Why?
|
Asthma | 1 | 2020 | 6234 | 0.050 |
Why?
|
Aged, 80 and over | 4 | 2022 | 58984 | 0.050 |
Why?
|
Self Report | 1 | 2013 | 3725 | 0.050 |
Why?
|
Bleomycin | 1 | 2022 | 494 | 0.050 |
Why?
|
Bacterial Proteins | 1 | 2014 | 3847 | 0.050 |
Why?
|
Polymerase Chain Reaction | 1 | 2010 | 6075 | 0.050 |
Why?
|
Hypertension | 2 | 2019 | 8540 | 0.050 |
Why?
|
Child, Preschool | 4 | 2022 | 42232 | 0.050 |
Why?
|
Etoposide | 1 | 2022 | 634 | 0.050 |
Why?
|
Skin Neoplasms | 1 | 2020 | 5821 | 0.050 |
Why?
|
Decision Making | 1 | 2014 | 3929 | 0.050 |
Why?
|
Cytomegalovirus Infections | 1 | 2007 | 831 | 0.040 |
Why?
|
Postnatal Care | 1 | 2022 | 262 | 0.040 |
Why?
|
Predictive Value of Tests | 2 | 2021 | 15266 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2017 | 10212 | 0.040 |
Why?
|
Longitudinal Studies | 3 | 2023 | 14608 | 0.040 |
Why?
|
Vincristine | 1 | 2022 | 1036 | 0.040 |
Why?
|
Sirolimus | 1 | 2007 | 1533 | 0.040 |
Why?
|
Boston | 2 | 2024 | 9327 | 0.040 |
Why?
|
Parity | 1 | 2022 | 927 | 0.040 |
Why?
|
Receptors, IgG | 1 | 2022 | 559 | 0.040 |
Why?
|
Drug Resistance, Viral | 1 | 2004 | 862 | 0.040 |
Why?
|
Internship and Residency | 1 | 2019 | 5882 | 0.040 |
Why?
|
Ferritins | 1 | 2022 | 598 | 0.040 |
Why?
|
Infant, Small for Gestational Age | 1 | 2021 | 461 | 0.040 |
Why?
|
Prognosis | 4 | 2021 | 29629 | 0.040 |
Why?
|
Pediatrics | 1 | 2013 | 3589 | 0.040 |
Why?
|
Prescriptions | 1 | 2021 | 386 | 0.040 |
Why?
|
Multicenter Studies as Topic | 1 | 2023 | 1702 | 0.040 |
Why?
|
Leukocyte Count | 1 | 2022 | 1596 | 0.040 |
Why?
|
Fetal Growth Retardation | 1 | 2021 | 580 | 0.040 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2011 | 4580 | 0.040 |
Why?
|
Research Design | 1 | 2013 | 6180 | 0.040 |
Why?
|
Fetal Blood | 1 | 2024 | 1347 | 0.040 |
Why?
|
Botswana | 1 | 2020 | 1048 | 0.040 |
Why?
|
Rwanda | 1 | 2019 | 665 | 0.030 |
Why?
|
Herpesvirus 4, Human | 1 | 2022 | 1078 | 0.030 |
Why?
|
Health Facilities | 1 | 2021 | 580 | 0.030 |
Why?
|
Aftercare | 1 | 2022 | 914 | 0.030 |
Why?
|
Antibodies, Bacterial | 1 | 2022 | 1469 | 0.030 |
Why?
|
Causality | 1 | 2022 | 1242 | 0.030 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2020 | 12149 | 0.030 |
Why?
|
Fatigue | 1 | 2023 | 1552 | 0.030 |
Why?
|
Temperature | 1 | 2022 | 2226 | 0.030 |
Why?
|
Time Factors | 5 | 2020 | 39969 | 0.030 |
Why?
|
Chronic Disease | 1 | 2011 | 9319 | 0.030 |
Why?
|
Comorbidity | 2 | 2020 | 10508 | 0.030 |
Why?
|
Birth Weight | 1 | 2023 | 2103 | 0.030 |
Why?
|
Paclitaxel | 1 | 2022 | 1732 | 0.030 |
Why?
|
Mozambique | 1 | 2014 | 55 | 0.030 |
Why?
|
Models, Theoretical | 2 | 2021 | 3575 | 0.030 |
Why?
|
Pharmaceutical Preparations | 1 | 2022 | 1089 | 0.030 |
Why?
|
Graft vs Host Disease | 1 | 2007 | 3029 | 0.030 |
Why?
|
Drug Therapy, Combination | 1 | 2004 | 6312 | 0.030 |
Why?
|
Quality-Adjusted Life Years | 1 | 2021 | 1722 | 0.030 |
Why?
|
Immunosuppressive Agents | 1 | 2007 | 4176 | 0.030 |
Why?
|
Endemic Diseases | 1 | 2015 | 190 | 0.030 |
Why?
|
Lung | 2 | 2024 | 10002 | 0.030 |
Why?
|
Sexual Behavior | 1 | 2023 | 2180 | 0.030 |
Why?
|
Radiography | 1 | 2024 | 6965 | 0.030 |
Why?
|
ROC Curve | 1 | 2021 | 3578 | 0.030 |
Why?
|
Respiratory Insufficiency | 1 | 2020 | 1230 | 0.020 |
Why?
|
Interleukin-6 | 1 | 2022 | 3208 | 0.020 |
Why?
|
Gene Products, nef | 1 | 2011 | 100 | 0.020 |
Why?
|
Infection Control | 1 | 2019 | 982 | 0.020 |
Why?
|
Enzyme-Linked Immunospot Assay | 1 | 2011 | 123 | 0.020 |
Why?
|
Antibodies, Viral | 1 | 2022 | 3156 | 0.020 |
Why?
|
Public Health | 1 | 2024 | 2669 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2021 | 3492 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 2022 | 4544 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2016 | 2850 | 0.020 |
Why?
|
Dermatology | 1 | 2020 | 918 | 0.020 |
Why?
|
Respiration, Artificial | 1 | 2020 | 2630 | 0.020 |
Why?
|
Length of Stay | 1 | 2023 | 6426 | 0.020 |
Why?
|
Risk Assessment | 1 | 2010 | 23996 | 0.020 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2007 | 5672 | 0.020 |
Why?
|
Patient Readmission | 1 | 2023 | 3271 | 0.020 |
Why?
|
Biopsy | 1 | 2020 | 6766 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2016 | 4853 | 0.020 |
Why?
|
Mental Health | 1 | 2022 | 3250 | 0.020 |
Why?
|
Critical Illness | 1 | 2021 | 2723 | 0.020 |
Why?
|
Practice Guidelines as Topic | 1 | 2004 | 7391 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2021 | 11120 | 0.020 |
Why?
|
Macrophages | 1 | 2020 | 5767 | 0.020 |
Why?
|
Demography | 1 | 2010 | 1648 | 0.020 |
Why?
|
Costs and Cost Analysis | 1 | 2011 | 1668 | 0.020 |
Why?
|
Registries | 1 | 2021 | 8225 | 0.020 |
Why?
|
Smoking | 1 | 2021 | 9053 | 0.010 |
Why?
|
Life Expectancy | 1 | 2011 | 1243 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2020 | 10194 | 0.010 |
Why?
|
Interferon-gamma | 1 | 2011 | 3162 | 0.010 |
Why?
|
Body Mass Index | 1 | 2020 | 12953 | 0.010 |
Why?
|
Aging | 1 | 2022 | 8710 | 0.010 |
Why?
|
Models, Statistical | 1 | 2014 | 5079 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 11742 | 0.010 |
Why?
|
Leukemia | 1 | 2007 | 1522 | 0.010 |
Why?
|
Transplantation, Homologous | 1 | 2007 | 4807 | 0.010 |
Why?
|
Quality Improvement | 1 | 2012 | 3802 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2019 | 15633 | 0.010 |
Why?
|
Recurrence | 1 | 2007 | 8466 | 0.010 |
Why?
|
Animals | 1 | 2004 | 168475 | 0.010 |
Why?
|
Quality of Life | 1 | 2012 | 13367 | 0.010 |
Why?
|